These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28244604)

  • 1. The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers.
    Xiang Q; Li C; Zhao X; Cui YM
    J Clin Pharm Ther; 2017 Jun; 42(3):345-349. PubMed ID: 28244604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers.
    Xiong Y; Yuan Z; Yang J; Xia C; Li X; Huang S; Zhang H; Liu M
    Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):117-24. PubMed ID: 25427746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
    Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
    Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
    Wan Z; Guo L; Li P; Zhao Z; Xu B; Ren L; Yan Y; Liu H; Zhang Y; Liu L
    J Clin Pharm Ther; 2020 Oct; 45(5):1159-1167. PubMed ID: 32562509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort.
    Zhao Y; Zhai D; He H; Li T; Chen X; Ji H
    Eur J Clin Pharmacol; 2009 Jun; 65(6):579-84. PubMed ID: 19205682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine.
    Guo LQ; Chen QY; Wang X; Liu YX; Chu XM; Cao XM; Li JH; Yamazoe Y
    Curr Drug Metab; 2007 Aug; 8(6):623-30. PubMed ID: 17691921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
    Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
    Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
    Zhou LY; Zuo XC; Chen K; Wang JL; Chen QJ; Zhou YN; Yuan H; Ma Y; Zhu LJ; Peng YX; Ming YZ
    J Clin Pharm Ther; 2016 Jun; 41(3):341-7. PubMed ID: 27149910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.
    Zhang JJ; Zhang H; Ding XL; Ma S; Miao LY
    Eur J Clin Pharmacol; 2013 Apr; 69(4):807-12. PubMed ID: 23097010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.
    Zhou S; Tao M; Wang Y; Wang L; Xie L; Chen J; Zhao Y; Liu Y; Zhang H; Ou N; Wang G; Shao F; Aa J
    Xenobiotica; 2019 Mar; 49(3):375-380. PubMed ID: 29521134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.
    Zheng T; Su CH; Zhao J; Zhang XJ; Zhang TY; Zhang LR; Kan QC; Zhang SJ
    Pharmazie; 2013 Apr; 68(4):257-60. PubMed ID: 23700791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.
    Wang XF; Yan L; Cao HM; Wei LM; Yang WH; Zhang SJ; Zhang LR
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):737-45. PubMed ID: 26104034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
    Xiang Q; Zhao X; Zhou Y; Duan JL; Cui YM
    J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.
    Xiang Q; Cui YM; Zhao X; Yan L; Zhou Y
    Pharmacology; 2012; 89(1-2):105-10. PubMed ID: 22398664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.
    Yin OQ; Tomlinson B; Chow MS
    J Clin Pharmacol; 2010 Oct; 50(10):1136-41. PubMed ID: 20133509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men.
    Yang G; Fu Z; Chen X; Yuan H; Yang H; Huang Y; Ouyang D; Tan Z; Tan H; Huang Z; Zhou H
    Clin Ther; 2011 Dec; 33(12):2060-70. PubMed ID: 22177374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.
    Yoo HD; Cho HY; Lee YB
    Br J Clin Pharmacol; 2010 Jan; 69(1):27-37. PubMed ID: 20078610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.